O	0	4	Late
O	5	12	cardiac
O	13	20	effects
O	21	23	of
B-intervention	24	32	adjuvant
I-intervention	33	45	chemotherapy
O	46	48	in
O	49	55	breast
O	56	62	cancer
O	63	72	survivors
O	73	80	treated
O	81	83	on
O	84	93	Southwest
O	94	102	Oncology
O	103	108	Group
O	109	117	protocol
O	118	123	s8897
O	123	124	.

O	125	128	The
O	129	133	late
O	134	141	cardiac
O	142	149	effects
O	150	152	of
O	153	161	adjuvant
O	162	175	anthracycline
O	176	183	therapy
O	184	186	in
O	187	196	survivors
O	197	199	of
O	200	205	early
O	205	206	-
O	206	211	stage
O	212	218	breast
O	219	225	cancer
O	226	230	have
O	231	234	had
O	235	242	limited
O	243	248	study
O	248	249	.

O	250	261	Subclinical
O	262	265	and
O	266	274	clinical
O	275	282	cardiac
O	283	287	late
O	288	295	effects
O	296	299	may
O	300	310	contribute
O	311	313	to
O	314	319	added
O	320	331	comorbidity
O	332	336	over
O	337	341	time
O	341	342	.

O	343	345	We
O	346	355	recruited
O	356	364	patients
O	365	372	treated
O	373	375	on
O	376	385	Southwest
O	386	394	Oncology
O	395	400	Group
O	401	402	(
O	402	406	SWOG
O	406	407	)
O	408	416	protocol
O	417	422	S8897
O	423	426	who
O	427	430	had
O	431	435	been
O	436	444	randomly
O	445	453	assigned
O	454	456	to
O	457	465	adjuvant
O	466	478	chemotherapy
O	479	483	with
O	484	486	or
B-control	487	494	without
I-control	495	506	doxorubicin
O	506	507	.

O	508	512	Left
O	513	524	ventricular
O	525	533	ejection
O	534	542	fraction
O	543	544	(
O	544	548	LVEF
O	548	549	)
O	550	553	was
O	554	563	evaluated
O	564	566	at
O	567	568	5
O	569	571	to
O	572	573	8
O	574	579	years
O	580	583	and
O	584	586	10
O	587	589	to
O	590	592	13
O	593	598	years
O	599	604	after
O	605	614	treatment
O	615	628	randomization
O	628	629	.

O	630	637	Cardiac
O	638	642	risk
O	643	650	factors
O	651	654	and
O	655	661	events
O	662	666	were
O	667	675	reported
O	676	678	by
O	679	689	clinicians
O	690	698	annually
O	699	706	between
O	707	710	the
O	711	714	two
O	715	726	assessments
O	726	727	.

O	728	729	A
O	730	735	total
O	736	738	of
B-total-participants	739	742	180
B-eligibility	743	749	breast
I-eligibility	750	756	cancer
I-eligibility	757	766	survivors
O	767	771	from
O	772	773	a
O	774	783	potential
O	784	790	sample
O	791	793	of
O	794	795	1
O	795	796	,
O	796	799	176
O	800	808	patients
O	809	813	were
O	814	821	entered
O	821	822	,
O	823	826	163
O	827	835	patients
O	836	838	at
O	839	840	5
O	841	843	to
O	844	845	8
O	846	851	years
O	852	855	and
O	856	858	17
O	859	869	additional
O	870	878	patients
O	879	881	at
O	882	884	10
O	885	887	to
O	888	890	13
O	891	896	years
O	896	897	,
O	898	902	with
O	903	905	93
O	906	918	longitudinal
O	919	930	assessments
O	931	933	of
O	934	938	LVEF
O	938	939	.

O	940	945	There
O	946	949	was
O	950	952	no
O	953	964	significant
O	965	975	difference
O	976	978	in
O	979	982	the
O	983	993	proportion
O	994	996	of
O	997	1002	women
O	1003	1007	with
O	1008	1010	an
B-outcome	1011	1015	LVEF
I-outcome	1016	1020	less
I-outcome	1021	1025	than
I-outcome	1026	1028	50
I-outcome	1028	1029	%
I-outcome	1030	1032	at
I-outcome	1033	1034	5
I-outcome	1035	1037	to
I-outcome	1038	1039	8
O	1040	1041	(
O	1041	1057	cyclophosphamide
O	1057	1058	,
O	1059	1070	doxorubicin
O	1070	1071	,
O	1072	1075	and
O	1076	1088	fluorouracil
O	1089	1090	[
O	1090	1093	CAF
O	1093	1094	]
O	1095	1096	v
O	1097	1113	cyclophosphamide
O	1113	1114	,
O	1115	1127	methotrexate
O	1127	1128	,
O	1129	1132	and
O	1133	1145	fluorouracil
O	1146	1147	[
O	1147	1150	CMF
O	1150	1151	]
O	1151	1152	:
B-iv-bin-percent	1153	1154	5
I-iv-bin-percent	1154	1155	%
O	1156	1157	v
B-cv-bin-percent	1158	1159	7
I-cv-bin-percent	1159	1160	%
O	1160	1161	;
O	1162	1163	P
O	1164	1165	=
O	1166	1167	.
O	1167	1169	68
O	1169	1170	)
O	1171	1173	or
B-outcome	1174	1176	10
I-outcome	1177	1179	to
I-outcome	1180	1182	13
I-outcome	1183	1188	years
O	1189	1190	(
O	1190	1193	CAF
O	1194	1195	v
O	1196	1199	CMF
O	1199	1200	:
B-iv-bin-percent	1201	1202	3
I-iv-bin-percent	1202	1203	%
O	1204	1205	v
B-cv-bin-percent	1206	1207	0
I-cv-bin-percent	1207	1208	%
O	1208	1209	;
O	1210	1211	P
O	1212	1213	=
O	1214	1215	.
O	1215	1217	16
O	1217	1218	)
O	1218	1219	;
O	1220	1227	however
O	1227	1228	,
O	1229	1231	in
O	1232	1234	an
O	1235	1246	exploratory
O	1247	1255	analysis
O	1255	1256	,
O	1257	1260	the
B-outcome	1261	1265	mean
I-outcome	1266	1270	LVEF
O	1271	1273	in
O	1274	1277	the
O	1278	1289	doxorubicin
O	1290	1295	group
O	1296	1299	was
O	1300	1313	statistically
O	1314	1327	significantly
O	1328	1333	lower
O	1334	1336	in
O	1337	1340	the
O	1341	1342	5
O	1342	1343	-
O	1344	1346	to
O	1347	1348	8
O	1348	1349	-
O	1349	1353	year
O	1354	1360	sample
O	1361	1362	(
B-iv-bin-percent	1362	1364	64
I-iv-bin-percent	1364	1365	.
I-iv-bin-percent	1365	1366	8
I-iv-bin-percent	1366	1367	%
O	1368	1369	v
B-cv-bin-percent	1370	1372	61
I-cv-bin-percent	1372	1373	.
I-cv-bin-percent	1373	1374	4
I-cv-bin-percent	1374	1375	%
O	1375	1376	;
O	1377	1378	P
O	1379	1380	=
O	1381	1382	.
O	1382	1384	01
O	1384	1385	)
O	1386	1389	but
O	1390	1393	not
O	1394	1396	in
O	1397	1400	the
O	1401	1403	10
O	1403	1404	-
O	1405	1407	to
O	1408	1410	13
O	1410	1411	-
O	1411	1415	year
O	1416	1422	sample
O	1422	1423	.

O	1424	1426	In
O	1427	1430	the
O	1431	1443	longitudinal
O	1444	1452	analysis
O	1452	1453	,
O	1454	1459	there
O	1460	1463	was
O	1464	1466	no
O	1467	1478	significant
O	1479	1492	deterioration
O	1493	1495	in
B-outcome	1496	1500	LVEF
O	1500	1501	.

O	1502	1507	Women
O	1508	1516	enrolled
O	1517	1521	onto
O	1522	1524	an
O	1525	1533	adjuvant
O	1534	1546	chemotherapy
O	1547	1556	treatment
O	1557	1565	clinical
O	1566	1571	trial
O	1572	1575	for
O	1576	1582	breast
O	1583	1589	cancer
O	1590	1594	were
O	1595	1607	successfully
O	1608	1617	recruited
O	1618	1620	to
O	1621	1632	participate
O	1633	1635	in
O	1636	1637	a
O	1638	1646	research
O	1647	1652	study
O	1653	1655	of
O	1656	1659	the
O	1660	1664	late
O	1665	1672	effects
O	1673	1675	of
O	1676	1685	treatment
O	1685	1686	,
O	1687	1695	although
O	1696	1700	many
O	1701	1705	SWOG
O	1706	1718	institutions
O	1719	1722	and
O	1723	1734	potentially
O	1735	1743	eligible
O	1744	1752	patients
O	1753	1758	chose
O	1759	1762	not
O	1763	1765	to
O	1766	1777	participate
O	1777	1778	.

O	1779	1781	In
O	1782	1786	this
O	1787	1795	selected
O	1796	1802	sample
O	1802	1803	,
O	1804	1808	with
O	1809	1811	up
O	1812	1814	to
O	1815	1817	13
O	1818	1823	years
O	1824	1826	of
O	1827	1833	follow
O	1833	1834	-
O	1834	1836	up
O	1836	1837	,
O	1838	1846	exposure
O	1847	1849	to
O	1850	1861	doxorubicin
O	1862	1865	did
O	1866	1869	not
O	1870	1878	increase
O	1879	1882	the
O	1883	1893	likelihood
O	1894	1896	of
O	1897	1904	adverse
O	1905	1912	cardiac
O	1913	1920	effects
O	1920	1921	.
